Cellectricon is a collaborative services provider dedicated to advance drug discovery and research in the areas of chronic pain and neurodegenerative disease. We are a team of highly experienced neurobiologists, stem cell researchers and engineers, with a proven track record of developing innovative in-vitro assays of enhanced translational value. With our unique drug discovery platform, we provide valuable decision-making information obtained from complex cell-based disease models. We always aim for long-term partnerships with our Clients, based on mutual trust and commitment.
Sponsors & Exhibitors
Ncardia believes that stem cell technology will help to get better medicines to patients faster. Ncardia develops produces and commercializes highly predictive human cellular assay systems for safety and efficacy testing. The product portfolio encompasses a broad panel of hiPSC-derived cardiac (Cor.4U®, Pluricytes®,vCor.4U® & FibroCor.4U®) and neural (CNS.4U®, Peri.4U® and Astro.4U®) cell types. In addition, the company delivers the CardioPlate™ product line of quality controlled ready-to-use assay plates. Ncardia delivers working assay solutions & extensive support.
a leader in in vivo
drug discovery whose capabilities include behavioral testing,
electrophysiology, EEG, histology, and microdialysis. Complementing its
extensive capabilities are a variety of mouse models, including transgenic
models, in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s
disease and psychosis/schizophrenia. PsychoGenics has also pioneered the
translation of rodent behavioral responses into robust, high-throughput, high
content phenotyping and its drug discovery platforms, SmartCube®, NeuroCube® and PhenoCube® have led to
shared risk partnerships with companies such as Sunovion and Roche and has
resulted in the discovery of several novel compounds in clinical trials or
advanced preclinical development.
from Charles River is industry-proven in the successful development of novel
therapies, with over 320 patents and 74 preclinical drug candidates delivered
to our sponsors in the past 17 years. Backed by more than 650 scientists, our
comprehensive, integrated portfolio employs the latest technology and platforms
to provide chemistry, biology, and pharmacology services that support clients from
the earliest stages of hit identification all the way through to IND. Our
client-focused, collaborative approach creates true partnerships that
anticipate challenges, overcome obstacles, and move us forward together on the
journey of getting new drugs to market.
As more than 60% of new drugs fail in phase 2, we have chosen to focus our activities since 2000 on preclinical in Vivo Efficacy Studies to offer better predictability and anticipate clinical results.
Syncrosome offer relevant disease models, cutting-edge techniques, specific Biomarkers and a comprehensive background of physiopathology to assist drug discovery companies in selecting their compounds.
Our main activities consit in:
In vitro Drug Efficacy Studiesfor:Central Nervous System with models in Parkinson, Alzheimer and Stroke disease.
In vivo Drug Efficacy Studies for:
Central Nervous System,
Cardiovascular and Metabolic disease,
Evotec is a globally operating drug discovery alliance and development partnership company headquartered in Hamburg, Germany. With over 2,100 highly experienced scientists and state-of-the-art technology platforms, Evotec provides comprehensive drug discovery solutions. The Company has key expertise in neuronal diseases, diabetes (including complications), pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Evotec identifies and develops first-in-class and best-in-class therapeutics for collaborators or for its own pipeline comprising approximately 100 co-owned product opportunities at different development stages.
Neuro-Sys, specialized in pharmacology, in vitro models for neurodegenerative diseases and High Content Imaging, provides its strong expertise to evaluate therapeutic molecules for Efficacy (E-FORM®) / Mode of action (MOAFORM®), from hit to drug candidate and repositioning projects:
QPS is well-known as a leading preclinical and clinical CRO for CNS Drug-Discovery and Development. We performed hundreds of efficacy and proof of concept studies with a wide range of transgenic in vivo models for neurodegenerative diseases and clinical studies in different phases with thousands of patients. In preclinical projects you will benefit from the experience gained during in vitro and in vivo projects with virtually all drug targets in Alzheimer’s, Parkinson’s, Huntington’s and other neurodegenerative diseases. Extensive behavioral, histological and biochemical evaluations will meet high expectations in terms of precision, quantitation and - very important - timely delivery.